Alexandra Canonici

发表

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

B. Hennessy, J. Crown, J. Meiller, 2020, Therapeutic advances in medical oncology.

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.

J. Crown, S. Madden, B. Browne, 2017, International journal of oncology.

Dual inhibition of IGF 1 R and ER enhances response to trastuzumab in HER 2 positive breast cancer cells

J. Crown, S. Madden, B. Browne, 2017 .

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

M. Duffy, R. Finn, J. Crown, 2013, Oncotarget.

Helicobacter pylori Counteracts the Apoptotic Action of Its VacA Toxin by Injecting the CagA Protein into Gastric Epithelial Cells

A. Sciullo, A. Oldani, M. Cormont, 2009, PLoS pathogens.

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

J. Crown, S. Madden, J. Meiller, 2023, PloS one.

Saccharomyces boulardii Improves Intestinal Epithelial Cell Restitution by Inhibiting αvβ5 Integrin Activation State

D. Czerucka, D. Lombardo, F. André, 2012, PloS one.

Saccharomyces boulardii Improves Intestinal Cell Restitution through Activation of the α2β1 Integrin Collagen Receptor

D. Czerucka, F. André, C. Siret, 2011, PloS one.

Insulin‐like growth factor‐I receptor, E‐cadherin and αv integrin form a dynamic complex under the control of α‐catenin

E. Bruyneel, F. van Roy, F. André, 2008 .

Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity

S. Garcia, P. Naquet, C. Bagnis, 2006, The Journal of experimental medicine.

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

E. McDermott, J. Crown, J. McCaffrey, 2019, Therapeutic advances in medical oncology.

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

J. Crown, D. Collins, N. Conlon, 2018, Investigational New Drugs.

Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin.

E. Bruyneel, F. van Roy, F. André, 2008, International journal of cancer.

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

M. Duffy, B. Hennessy, J. Crown, 2020, Investigational New Drugs.

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

B. Hennessy, J. Crown, A. Blanco, 2023, British Journal of Cancer.

Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines.

J. Crown, B. Browne, N. O'Donovan, 2012 .

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

M. Duffy, R. Finn, J. Crown, 2013, Oncotarget.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

J. Crown, B. Browne, D. Collins, 2018, Investigational New Drugs.

Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity

S. Garcia, P. Naquet, C. Bagnis, 2006, The Journal of experimental medicine.